Myelodysplastic syndrome.
Indian J Pediatr
;
2008 Jul; 75(7): 729-32
Artigo
em Inglês
| IMSEAR
| ID: sea-82211
ABSTRACT
Pediatric myelodysplastic syndrome (MDS), though rare, constitutes a distinct entity quite different from adult MDS. They have unique clinical features, aggressive clinical course with an overall mean survival of only 9.9 months. A pediatric approach to the WHO classification has become necessary since the WHO classification of MDS has failed to address the uniqueness of pediatric MDS. A new prognostic system also needs to be evolved since the international prognostic system has limited prognostic impact in children. Intensive chemotherapy such as the one used in de novo-acute myeloid leukemia (AML) leads to complete remission in some children and this may be the treatment of choice in pediatric MDS.
Texto completo:
DisponíveL
Índice:
IMSEAR (Sudeste Asiático)
Assunto principal:
Prognóstico
/
Síndromes Mielodisplásicas
/
Humanos
/
Leucemia Mieloide Aguda
/
Criança
/
Fatores Etários
/
Diagnóstico Diferencial
Tipo de estudo:
Estudo diagnóstico
/
Estudo prognóstico
Idioma:
Inglês
Revista:
Indian J Pediatr
Ano de publicação:
2008
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS